AroCell AB: announces that a distribution agreemen
Post# of 301275
"We very much look forward to this new collaboration with the England based Pathway Diagnostics for the distribution of our TK 210 ELISA test", states Jan Stålemark, AroCell CEO. "Pathway Diagnostics Ltd is a leading supplier of specialist clinical and research diagnostics in the UK and was established in 1998 to provide high quality in-vitro diagnostic products and instrumentation to clinical, research and industrial laboratories mainly in the UK and Ireland. Pathway Diagnostics are highly focused on the needs of their customers and in providing the highest quality products and service and therefore we consider them as a perfect match for our TK 210 ELISA test."
The TK 210 ELISA test will be commercially available immediately through Pathway Diagnostics in the UK and Irish market.
For additional information: Jan Stålemark, CEO AroCell AB (publ) Tel: +46(0)706926206 info@arocell.com www.arocell.com
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 08:50 CET on 13 October 2017.
About AroCell AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure (Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provide valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com . Redeye AB is AroCell's Certified Adviser.
Attachments:
(0)
(0)